Proteome Systems hits second milestone in the development of a rapid diagnostic test to detect active TB

24-Mar-2006

Proteome Systems announced that its international partner, the Foundation for Innovative New Diagnostics (FIND), has signed off on the second Milestone in its Tuberculosis [TB] diagnostic program. Proteome Systems has discovered and patented TB proteins in human sputum and blood that can be used to diagnose active tuberculosis. There is currently no point-of-care [POC] test to detect TB in its active form. This recent milestone involved producing and using antibodies for the detection of these unique TB proteins in clinical samples.

FIND CEO Giorgio Roscigno said that reaching this second milestone is important particularly as it coincides with World TB Day when partners worldwide are renewing their commitment to rally behind the new ten- year Global Plan to stop TB (2006-2015).

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous